Literature DB >> 19454433

Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

R Dummer1, A Hauschild, G Pentheroudakis.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19454433     DOI： 10.1093/annonc/mdp152

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  11 in total

1.  The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells.

Authors:  Maithao N Le; Joseph L-K Chan; Stephen A Rosenberg; Adam S Nabatian; Kim T Merrigan; Karine A Cohen-Solal; James S Goydos
Journal:  J Invest Dermatol       Date:  2010-05-27       Impact factor: 8.551

2.  Hypopigmented scar formation after application of over-the-counter wart and mole removal cream.

Authors:  Said Hilton; Günter Reinerth; Heike Heise; Bettina A Buhren; Edwin Bölke; Peter A Gerber
Journal:  Wien Klin Wochenschr       Date:  2011-03-01       Impact factor: 1.704

Review 3.  Long-term follow-up for melanoma patients: is there any evidence of a benefit?

Authors:  Natasha M Rueth; Kate D Cromwell; Janice N Cormier
Journal:  Surg Oncol Clin N Am       Date:  2015-01-24       Impact factor: 3.495

Review 4.  Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review.

Authors:  Kate D Cromwell; Merrick I Ross; Yan Xing; Jeffrey E Gershenwald; Richard E Royal; Anthony Lucci; Jeffrey E Lee; Janice N Cormier
Journal:  Melanoma Res       Date:  2012-10       Impact factor: 3.599

5.  Breast and cervical cancer screening behaviours among colorectal cancer survivors in Nova Scotia.

Authors:  M Corkum; R Urquhart; G Kephart; J A Hayden; G Porter
Journal:  Curr Oncol       Date:  2014-10       Impact factor: 3.677

Review 6.  F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review.

Authors:  Milly A Schröer-Günther; Robert F Wolff; Marie E Westwood; Fülöp J Scheibler; Christoph Schürmann; Brigitta G Baumert; Stefan Sauerland; Jos Kleijnen
Journal:  Syst Rev       Date:  2012-12-13

7.  Prognostic value of [18F]-fluoro-deoxy-glucose PET/CT, S100 or MIA for assessment of cancer-associated mortality in patients with high risk melanoma.

Authors:  Markus Essler; Anna Link; Benedetta Belloni; Vesna Mirceva; Michael Souvatzoglou; Markus Thaler; Bernhard Haller; Ruediger Hein; Bernd J Krause
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

Review 8.  Repressing CD147 is a novel therapeutic strategy for malignant melanoma.

Authors:  Xing Hu; Juan Su; Youyou Zhou; Xiaoyun Xie; Cong Peng; Zhimin Yuan; Xiang Chen
Journal:  Oncotarget       Date:  2017-04-11

9.  Association of Innovations in Radiotherapy and Systemic Treatments With Clinical Outcomes in Patients With Melanoma Brain Metastasis From 2007 to 2016.

Authors:  Harry C Brastianos; Paul Nguyen; Arjun Sahgal; Elizabeth A Eisenhauer; Tara Baetz; Timothy P Hanna
Journal:  JAMA Netw Open       Date:  2020-07-01

Review 10.  Susceptibility and Resistance Mechanisms During Photodynamic Therapy of Melanoma.

Authors:  Xin-Ying Li; Liu-Chang Tan; Li-Wen Dong; Wan-Qi Zhang; Xiao-Xiao Shen; Xiao Lu; Hong Zheng; Yuan-Gang Lu
Journal:  Front Oncol       Date:  2020-05-12       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.